NCT07363382 The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
| NCT ID | NCT07363382 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | First Affiliated Hospital of Fujian Medical University |
| Condition | Prostate Cancer (Adenocarcinoma) |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2025-12-20 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 6 participants in total. It began in 2025-12-20 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.
Eligibility Criteria
Inclusion Criteria: * confirmed treated or untreated prostate cancer patients; * signed written consent. Exclusion Criteria: * known allergy against PSMA; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Contact & Investigator
Weibing Miao, MD
PRINCIPAL INVESTIGATOR
First Affiliated Hospital of Fujian Medical University
Frequently Asked Questions
Who can join the NCT07363382 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 90 Years, studying Prostate Cancer (Adenocarcinoma). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07363382 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07363382 currently recruiting?
Yes, NCT07363382 is actively recruiting participants. Contact the research team at miaoweibing@126.com for enrollment information.
Where is the NCT07363382 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT07363382 clinical trial?
NCT07363382 is sponsored by First Affiliated Hospital of Fujian Medical University. The principal investigator is Weibing Miao, MD at First Affiliated Hospital of Fujian Medical University. The trial plans to enroll 6 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.